Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Birch, 2001, Relative frequency and morphology of cancers in carriers of germline TP53 mutations, Oncogene, 20, 4621, 10.1038/sj.onc.1204621

Brachmann, 1996, Dominant-negative p53 mutations selected in yeast hit cancer hotspots, Proc Natl Acad Sci USA, 93, 4091, 10.1073/pnas.93.9.4091

Dearth, 2007, Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers, Carcinogenesis, 28, 289, 10.1093/carcin/bgl132

Denissenko, 1996, Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53, Science, 274, 430, 10.1126/science.274.5286.430

Hainaut, 2000, p53 and human cancer: the first ten thousand mutations, Adv Cancer Res, 77, 81, 10.1016/S0065-230X(08)60785-X

Hsiao, 1994, Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness, Am J Pathol, 145, 702

Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc Natl Acad Sci USA, 100, 8424, 10.1073/pnas.1431692100

Lang, 2004, Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome, Cell, 119, 861, 10.1016/j.cell.2004.11.006

Lunter, 2004, A nucleotide substitution model with nearest-neighbour interactions, Bioinformatics, 20, I216, 10.1093/bioinformatics/bth901

Malkin, 1990, Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Science, 250, 1233, 10.1126/science.1978757

Mathe, 2006, Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods, Nucleic Acids Res, 34, 1317, 10.1093/nar/gkj518

Maurici, 2001, Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay, Oncogene, 20, 3533, 10.1038/sj.onc.1204428

Olive, 2004, Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome, Cell, 119, 847, 10.1016/j.cell.2004.11.004

Olivier, 2002, The IARC TP53 database: new online mutation analysis and recommendations to users, Hum Mutat, 19, 607, 10.1002/humu.10081

Olivier, 2003, Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype, Cancer Res, 63, 6643

Olivier, 2004, TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer, IARC Sci Publ, 157, 247

Olivier, 2006, The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer, Clin Cancer Res, 12, 1157, 10.1158/1078-0432.CCR-05-1029

Pan, 2000, Identification of a tumor-derived p53 mutant with novel transactivating selectivity, Oncogene, 19, 3095, 10.1038/sj.onc.1203663

Smith, 1999, Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions, Oncogene, 18, 2451, 10.1038/sj.onc.1202565

Varley, 1997, A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene, Oncogene, 14, 865, 10.1038/sj.onc.1201041

Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675

Wong, 2006, Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome, Gastroenterology, 130, 73, 10.1053/j.gastro.2005.10.014

Zajac, 2000, A double germline mutations in the APC and p53 genes, Neoplasma, 47, 335